To include your compound in the COVID-19 Resource Center, submit it here.

$8B Loxo deal yields first drug with approval of Lilly’s targeted lung cancer therapy

Retevmo selpercatinib becomes the first targeted therapy approved for RET-driven cancers

FDA’s approval of Retevmo selpercatinib from Eli Lilly is the second approval for a genetically defined subset of non-small cell lung cancer patients this week.

The selective RET inhibitor is the first product of the $8 billion takeout of Loxo Oncology Inc. by Eli Lilly and Co. (NYSE:LLY) last year to reach the market,

Read the full 540 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE